Sorafenib therapy for advanced hepatocellular carcinoma with Vp3 or 4 portal vein tumor thrombosis

Teiji Kuzuya; Kaoru Tsuchiya; Keisuke Tanaka; Yuichiro Suzuki; Takahide Hoshioka; Shinji Tamaki; Tomoji Kato; Yutaka Yasui; Takahiro Hosokawa; Ken Ueda; Hiroyuki Nakanishi; Jun Itakura; Yuka Takahashi; Masayuki Kurosaki; Yasuhiro Asahina; Namiki Izumi

doi:10.2957/kanzo.52.325

Sorafenib therapy for advanced hepatocellular carcinoma with Vp3 or 4 portal vein tumor thrombosis

Teiji Kuzuya
, Kaoru Tsuchiya
, Keisuke Tanaka
, Yuichiro Suzuki
, Takahide Hoshioka
, Shinji Tamaki
, Tomoji Kato
, Yutaka Yasui
, Takahiro Hosokawa
, Ken Ueda
, Hiroyuki Nakanishi
, Jun Itakura
, Yuka Takahashi
, Masayuki Kurosaki
, Yasuhiro Asahina
, Namiki Izumi

Research output: Contribution to journal › Article › peer-review

Abstract

We investigated efficacy of sorafenib therapy for advanced hepatocellular carcinoma (HCC) with Vp3/4 portal vein tumor thrombosis. According to modified RECIST, the therapeutic responses in Vp0/2 group (n=30) were 8 PR, 14 SD and 8 PD cases, and while those in Vp3/4 group (n=11) were 5 PR, 2 SD and 4 PD cases. The response rates and cumulative progression rates were not significantly different between two groups. The cumulative survival rates in Vp3/4 group were significantly lower than those in Vp0/2 group. The deteriorations of Child-Pugh scores in Vp3/4 group were significantly higher than those in Vp0/2 group. The possibility of the deterioration of liver function should be kept in mind during sorafenib therapy for advanced HCC with Vp3/4.

Original language	English
Pages (from-to)	325-326
Number of pages	2
Journal	Kanzo/Acta Hepatologica Japonica
Volume	52
Issue number	5
DOIs	https://doi.org/10.2957/kanzo.52.325
Publication status	Published - 2011
Externally published	Yes

All Science Journal Classification (ASJC) codes

Hepatology

Access to Document

10.2957/kanzo.52.325

Cite this

Kuzuya, T., Tsuchiya, K., Tanaka, K., Suzuki, Y., Hoshioka, T., Tamaki, S., Kato, T., Yasui, Y., Hosokawa, T., Ueda, K., Nakanishi, H., Itakura, J., Takahashi, Y., Kurosaki, M., Asahina, Y., & Izumi, N. (2011). Sorafenib therapy for advanced hepatocellular carcinoma with Vp3 or 4 portal vein tumor thrombosis. Kanzo/Acta Hepatologica Japonica, 52(5), 325-326. https://doi.org/10.2957/kanzo.52.325

@article{cddc21d9767a4816b024610ffcd2c4e9,

title = "Sorafenib therapy for advanced hepatocellular carcinoma with Vp3 or 4 portal vein tumor thrombosis",

abstract = "We investigated efficacy of sorafenib therapy for advanced hepatocellular carcinoma (HCC) with Vp3/4 portal vein tumor thrombosis. According to modified RECIST, the therapeutic responses in Vp0/2 group (n=30) were 8 PR, 14 SD and 8 PD cases, and while those in Vp3/4 group (n=11) were 5 PR, 2 SD and 4 PD cases. The response rates and cumulative progression rates were not significantly different between two groups. The cumulative survival rates in Vp3/4 group were significantly lower than those in Vp0/2 group. The deteriorations of Child-Pugh scores in Vp3/4 group were significantly higher than those in Vp0/2 group. The possibility of the deterioration of liver function should be kept in mind during sorafenib therapy for advanced HCC with Vp3/4.",

keywords = "Hepatocellular carcinoma, Sorafenib, Vp3 or 4 portal vein tumor thrombosis",

author = "Teiji Kuzuya and Kaoru Tsuchiya and Keisuke Tanaka and Yuichiro Suzuki and Takahide Hoshioka and Shinji Tamaki and Tomoji Kato and Yutaka Yasui and Takahiro Hosokawa and Ken Ueda and Hiroyuki Nakanishi and Jun Itakura and Yuka Takahashi and Masayuki Kurosaki and Yasuhiro Asahina and Namiki Izumi",

year = "2011",

doi = "10.2957/kanzo.52.325",

language = "English",

volume = "52",

pages = "325--326",

journal = "Kanzo/Acta Hepatologica Japonica",

issn = "0451-4203",

publisher = "Japan Society of Hepatology",

number = "5",

}

Kuzuya, T, Tsuchiya, K, Tanaka, K, Suzuki, Y, Hoshioka, T, Tamaki, S, Kato, T, Yasui, Y, Hosokawa, T, Ueda, K, Nakanishi, H, Itakura, J, Takahashi, Y, Kurosaki, M, Asahina, Y & Izumi, N 2011, 'Sorafenib therapy for advanced hepatocellular carcinoma with Vp3 or 4 portal vein tumor thrombosis', Kanzo/Acta Hepatologica Japonica, vol. 52, no. 5, pp. 325-326. https://doi.org/10.2957/kanzo.52.325

TY - JOUR

T1 - Sorafenib therapy for advanced hepatocellular carcinoma with Vp3 or 4 portal vein tumor thrombosis

AU - Kuzuya, Teiji

AU - Tsuchiya, Kaoru

AU - Tanaka, Keisuke

AU - Suzuki, Yuichiro

AU - Hoshioka, Takahide

AU - Tamaki, Shinji

AU - Kato, Tomoji

AU - Yasui, Yutaka

AU - Hosokawa, Takahiro

AU - Ueda, Ken

AU - Nakanishi, Hiroyuki

AU - Itakura, Jun

AU - Takahashi, Yuka

AU - Kurosaki, Masayuki

AU - Asahina, Yasuhiro

AU - Izumi, Namiki

PY - 2011

Y1 - 2011

N2 - We investigated efficacy of sorafenib therapy for advanced hepatocellular carcinoma (HCC) with Vp3/4 portal vein tumor thrombosis. According to modified RECIST, the therapeutic responses in Vp0/2 group (n=30) were 8 PR, 14 SD and 8 PD cases, and while those in Vp3/4 group (n=11) were 5 PR, 2 SD and 4 PD cases. The response rates and cumulative progression rates were not significantly different between two groups. The cumulative survival rates in Vp3/4 group were significantly lower than those in Vp0/2 group. The deteriorations of Child-Pugh scores in Vp3/4 group were significantly higher than those in Vp0/2 group. The possibility of the deterioration of liver function should be kept in mind during sorafenib therapy for advanced HCC with Vp3/4.

AB - We investigated efficacy of sorafenib therapy for advanced hepatocellular carcinoma (HCC) with Vp3/4 portal vein tumor thrombosis. According to modified RECIST, the therapeutic responses in Vp0/2 group (n=30) were 8 PR, 14 SD and 8 PD cases, and while those in Vp3/4 group (n=11) were 5 PR, 2 SD and 4 PD cases. The response rates and cumulative progression rates were not significantly different between two groups. The cumulative survival rates in Vp3/4 group were significantly lower than those in Vp0/2 group. The deteriorations of Child-Pugh scores in Vp3/4 group were significantly higher than those in Vp0/2 group. The possibility of the deterioration of liver function should be kept in mind during sorafenib therapy for advanced HCC with Vp3/4.

KW - Hepatocellular carcinoma

KW - Sorafenib

KW - Vp3 or 4 portal vein tumor thrombosis

UR - https://www.scopus.com/pages/publications/79959361937

UR - https://www.scopus.com/pages/publications/79959361937#tab=citedBy

U2 - 10.2957/kanzo.52.325

DO - 10.2957/kanzo.52.325

M3 - Article

AN - SCOPUS:79959361937

SN - 0451-4203

VL - 52

SP - 325

EP - 326

JO - Kanzo/Acta Hepatologica Japonica

JF - Kanzo/Acta Hepatologica Japonica

IS - 5

ER -

Sorafenib therapy for advanced hepatocellular carcinoma with Vp3 or 4 portal vein tumor thrombosis

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this